Cellectis (CLLS) Enterprise Value (2014 - 2026)
Cellectis (CLLS) posted Enterprise Value of -$212.4 million for Q1 2026, down 1.77% on a QoQ basis from -$208.7 million in Q4 2025, and up 12.86% year-over-year from -$188.2 million in Q1 2025.
Cellectis (CLLS) has 13 years of Enterprise Value data on file, last reported at -$212.4 million in Q1 2026.
- In Q1 2026, Enterprise Value rose 12.86% year-over-year to -$212.4 million; the TTM figure through Mar 2026 stood at -$212.4 million (up 12.86% YoY), while the FY2025 annual figure was -$208.7 million, up 19.84% from the prior year.
- Enterprise Value fell to -$212.4 million in Q1 2026, from -$208.7 million in the prior quarter.
- Across five years, Enterprise Value topped out at $8.0 million in Q4 2022 and bottomed at -$283.2 million in Q3 2025.
- A 5-year average of -$170.7 million and a median of -$208.7 million in 2025 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value jumped 104.66% — and 2023, when it sank 2504.47%.
- Year by year, Enterprise Value stood at $8.0 million in 2022, then sank by 2504.47% to -$191.7 million in 2023, then sank by 35.78% to -$260.3 million in 2024, then advanced by 19.84% to -$208.7 million in 2025, then dropped by 1.77% to -$212.4 million in 2026.
- The last three Enterprise Value figures came in at -$212.4 million (Q1 2026), -$208.7 million (Q4 2025), and -$283.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | -212.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -212.36 Mn |
| Dec 31, 2025 | -208.66 Mn |
| Sep 30, 2025 | -283.23 Mn |
| Jun 30, 2025 | -198.15 Mn |
| Mar 31, 2025 | -243.69 Mn |
| Dec 31, 2024 | -260.31 Mn |
| Sep 30, 2024 | -238.57 Mn |
| Jun 30, 2024 | -260.47 Mn |
| Mar 31, 2024 | -226.84 Mn |
| Dec 31, 2023 | -191.71 Mn |
| Sep 30, 2023 | -93.22 Mn |
| Jun 30, 2023 | -80.09 Mn |
| Mar 31, 2023 | -81.41 Mn |
| Dec 31, 2022 | 7.97 Mn |
| Sep 30, 2022 | -110.04 Mn |
| Jun 30, 2022 | -150.27 Mn |
| Mar 31, 2022 | -17.22 Mn |
| Dec 31, 2021 | 15.18 Mn |
| Sep 30, 2021 | -186.92 Mn |
| Jun 30, 2021 | -225.16 Mn |
| Mar 31, 2021 | 6.86 Mn |
| Dec 31, 2020 | -243.19 Mn |
| Sep 30, 2020 | -266.34 Mn |
| Jun 30, 2020 | -353.45 Mn |
| Mar 31, 2020 | -307.39 Mn |
| Dec 31, 2019 | -347.79 Mn |
| Sep 30, 2019 | -321.73 Mn |
| Jun 30, 2019 | -410.61 Mn |
| Mar 31, 2019 | -419.36 Mn |
| Dec 31, 2018 | -410.92 Mn |
| Sep 30, 2018 | -435.24 Mn |
| Jun 30, 2018 | -450.04 Mn |
| Mar 31, 2018 | -275.67 Mn |
| Dec 31, 2017 | -292.67 Mn |
| Sep 30, 2017 | -286.37 Mn |
| Jun 30, 2017 | -300.55 Mn |
| Mar 31, 2017 | -273.32 Mn |
| Dec 31, 2016 | -296.32 Mn |
| Sep 30, 2016 | -293.00 Mn |
| Jun 30, 2016 | -452.85 Mn |
| Mar 31, 2016 | -440.69 Mn |
| Dec 31, 2015 | -343.65 Mn |
| Sep 30, 2015 | -124.67 Mn |
| Jun 30, 2015 | -123.98 Mn |
| Mar 31, 2015 | -128.09 Mn |
| Dec 31, 2014 | -11.02 Mn |